Aspirin effective in cutting bowel cancer death risk

26 Apr 2012

1

Researchers in the Netherlands have found that bowel cancer patients who took the painkiller aspirin for at least nine months after diagnosis cut the risk of dying from the disease by 30 per cent.

The study also revealed that patients taking it for any length of time following diagnosis cut the odds by 23 per cent compared as against not taking it at all, according to the New York Daily News.

As many as 4,500 patients diagnosed underwent tests between 1998 and 2007.

According to the latest evidence, the drug not only reduced the risk of dying from cancer, but could also help eliminate chances of developing  the disease in the first place.

A quarter of those tested were not aspirin users, while another quarter only took aspirin after diagnosis, and the remaining group took the drug both before and after developing cancer.

According to Dr Gerrit-Jan Liefers, from Leiden University Medical Centre, the team's findings could have profound implications for clinical practice. He added that the team had shown the therapeutic effect of a widely-available, familiar drug that cost mere pennies per day.

Latest articles

UK weighs faster defence spending hike toward 3% as security pressures mount

UK weighs faster defence spending hike toward 3% as security pressures mount

China opens market to 53 African nations in zero-tariff pivot

China opens market to 53 African nations in zero-tariff pivot

Modi’s rooftop solar push slows as lenders and states drag feet

Modi’s rooftop solar push slows as lenders and states drag feet

India hosts global AI summit as tech leaders gather in Delhi amid investment push

India hosts global AI summit as tech leaders gather in Delhi amid investment push

OpenClaw founder Peter Steinberger joins OpenAI as personal-agent project moves to foundation

OpenClaw founder Peter Steinberger joins OpenAI as personal-agent project moves to foundation

Fractal Analytics shares slip on debut as AI uncertainty weighs on sentiment

Fractal Analytics shares slip on debut as AI uncertainty weighs on sentiment

Warner Bros weighs reopening sale talks with Paramount amid competing bids

Warner Bros weighs reopening sale talks with Paramount amid competing bids

ByteDance pledges safeguards for Seedance AI after studios raise IP concerns

ByteDance pledges safeguards for Seedance AI after studios raise IP concerns

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China